Novartis to pay $125M for blood-brain barrier crossing platform

{
  "signal_id": "8f30d188-0846-9edf-c8eb-658316ab1231",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-09-16T20:26:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.biopharmadive.com/news/novartis-125m-for-blood-brain-barrier-crossing-platform-Sironax/830560/",
    "title": "Novartis to pay $125M for blood-brain barrier crossing platform",
    "author": "Delilah Alvarado",
    "excerpt": "Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential. Novartis will pay $125 million up front for rights to a delivery platform designed to get drugs into the brain. Sironax, a Boston-area biotechnology company, said Tuesday that Novartis has exercised an option to acquire full ownership of that startup's brain delivery platform. Sironax's technology is meant to overcome a major challenge in neurological drug development: delivering therapeutics across the \"blood-brain barrier.\" Sironax will receive the nine-figure payout following the close of the transaction and will continue to retain rights to develop, manufacture, and commercialize certain assets with the platform. The company currently has three programs in early-stage trials that it plans to move forward using the purchase proceeds. “This achievement comes at a pivotal time as we advance our clinical-stage pipeline and accelerate the development of promising new therapies,” said Shefali Agarwal, President and CEO of Sironax, in a statement. Developing medications that can cross the blood-brain barrier has been a critical challenge for both small startups and large pharmaceutical companies. This obstacle acts like a protective filter, shielding the organ from toxic substances as well as...",
    "product": "brain delivery platform",
    "summary": "Novartis is acquiring full ownership of Sironax's brain delivery platform for an upfront payment of $125 million.",
    "planning": true,
    "image_url": "https://imgproxy.divecdn.com/Y0IV0cdvYBAkDibRunCGb7IyNOwTrvGQvljJejTlgz0/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA5Nzg4MDE4LmpwZw==.webp",
    "confidence": 0.95,
    "product_data": {
      "name": "brain delivery platform",
      "full_text": "brain delivery platform",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-16T20:26:00Z",
    "article_sentence": "Novartis will pay $125 million up front for rights to a delivery platform designed to get drugs into the brain.",
    "amount_normalized": 125000000,
    "related_company_name": "Sironax",
    "related_company_domain": "sironax.com"
  }
}

curl https://signals.autobound.ai/v1/signals/8f30d188-0846-9edf-c8eb-658316ab1231 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novartis.com","limit":20}'